Ferric Carboxymaltose

Ferric Carboxymaltose should be administered by staff that is trained in dealing with serious allergic reactions (anaphylactic reaction). Ferric Carboxymaltose can be administered as an undiluted injection, directly into the vein or via a dialyzer if the patient is on dialysis. It can also be diluted with sodium chloride and given as infusion directly into the vein. The patient should be monitored for at least 30 minutes after each injection. Also, the injection should not be given below the skin (subcutaneous route) or in the muscle (intramuscular route).

Ferric Carboxymaltose vials should be stored at 20°C to 25°C (68°F to 77°F). Remember, these should not be freezed. The temperature should not deviate more than 15°C to 30°C (59°F to 86°F).

Usually, two doses of this medicine are given 7 days apart. The hemoglobin is then assessed at least 4 weeks after the final injection to allow time for the RBCs to form. If the reports still show deficiency of iron, it can be re-administered depending on individual need.

Yes, Ferric Carboxymaltose may cause a temporary increase in blood pressure accompanied with facial flushing, dizziness, and nausea. This may occur immediately after you take the medicine and generally disappears within 30 minutes.

Incorrect administration of Ferric Carboxymaltose may cause leakage of the medicine at the administration site. The administration must be stopped immediately if there is some leakage. The leakage may cause skin irritation and long-lasting brown discoloration of skin at the administration site.

There is limited data on the use of Ferric Carboxymaltose in pregnancy. It is important to tell your doctor if you are pregnant or are planning to have a baby. Consult your doctor if you become pregnant during treatment with Ferric Carboxymaltose. Your doctor will decide whether you need to continue treatment or discontinue it.